Clinical trials: Tocilizumab
Rheumatoid Arthritis
Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis
This multi-center, observational study will evaluate the clinical practice patterns, efficacy and safety of RoActemra/Actemra in patients with rheumatoid arthritis who have had an inadequate response (or were intolerant to)…
- Trial name
- NCT01579006
- Testing
- Tocilizumab
- Where
- 14 sites in Israel
- Volunteers
- 184 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Study of Tocilizumab as Monotherapy or in Combination With DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis
This open-label single-arm study will evaluate the safety, tolerability and efficacy of tocilizumab [RoActemra/Actemra] in patients with moderate to severe rheumatoid arthritis who experience an inadequate clinical response to a…
- Trial name
- NCT01089023
- Testing
- tocilizumab [RoActemra/Actemra]
- Where
- 9 sites in Bahrain, Iran and 3 more
- Volunteers
- 95 people
- Sponsor
- Hoffmann-La Roche
HIV Infections
AIDS 347: IL-6 Blockade in Treated HIV Infection
The study is a phase I/II, double-blind, placebo-controlled, randomized cross-over clinical trial of tocilizumab (TCZ) or placebo in HIV-infected subjects receiving antiretroviral therapy with suppressed viral replication and…
- Trial name
- IL-6 (NCT02049437)
- Testing
- tocilizumab
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Case Western Reserve University
Rheumatoid Arthritis
An Observational Study of the Impact of RoActemra/Actemra on Fatigue in Patients With Rheumatoid Arthritis (PEPS)
This prospective, observational study will assess the effect of RoActemra/Actemra (tocilizumab) on fatigue in patients with moderate to severe rheumatoid arthritis who have an inadequate response to disease-modifying…
- Trial name
- NCT01185522
- Where
- France
- Volunteers
- 719 people
- Sponsor
- Hoffmann-La Roche
SARS-CoV 2
Efficacy of Tocilizumab on Patients With COVID-19
This is a randomized, double blind, multi-center study to evaluate the effects of tocilizumab compared to placebo on patient outcomes in participants with confirmed SARS-CoV-2 infection and evidence of systemic inflammation.
- Trial name
- NCT04356937
- Testing
- Tocilizumab
- Where
- 3 sites in United States
- Volunteers
- 243 people
- Sponsor
- Massachusetts General Hospital
Rheumatoid Arthritis
Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Participants With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Non-Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) and/or Anti-tumor Necrosis Factor (Anti-TNF) Therapy
This observational study will evaluate the safety, tolerability and efficacy of tocilizumab in participants with moderate to severe RA who have an inadequate response to current non-biologic DMARD and/or anti-TNF therapy.
- Trial name
- NCT01362062
- Testing
- Tocilizumab
- Where
- 7 sites in India
- Volunteers
- 110 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Study of Tocilizumab With or Without Methotrexate in Patients With Rheumatoid Arthritis.
This open-label, single-arm, non-randomized study will evaluate the adherence and persistence to tocilizumab therapy in patients with moderate to severe active rheumatoid arthritis, who have an inadequate clinical response to…
- Trial name
- NCT01010503
- Testing
- tocilizumab [RoActemra/Actemra]
- Where
- Slovakia
- Volunteers
- 32 people
- Sponsor
- Hoffmann-La Roche
Hematologic Malignancy
PROACTIVE: Preventing Acute/Chronic GVHD With TocIlizumab Combined With GVHD Prophylaxis Post allogEneic Transplant
This is a phase II open-label trial designed to evaluate the efficacy of tocilizumab in improving GVHD-free/relapse-free survival (GRFS) after allogeneic hematopoietic cell transplantation (alloHCT) for hematologic malignancy.
- Trial name
- NCT03699631
- Testing
- Tacrolimus, Methotrexate, Tocilizumab
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Medical College of Wisconsin
Rheumatoid Arthritis
A Study to Understand How Effective is Tofacitinib When Compared to Other Advanced Treatments in Patients With Rheumatoid Arthritis
The purpose of this study is to learn how different types of medicines may improve disease activity in people with rheumatoid arthritis (RA). RA is a kind of joint disease that causes pain and swelling.
- Trial name
- NCT06418529
- Testing
- tofacitinib, tumor necrosis factor inhibitors (TNFi), abatacept
- Where
- United States
- Volunteers
- 21,340 people
- Sponsor
- Pfizer
Juvenile Idiopathic Arthritis
A Study of Decreased Dose Frequency in Participants With Systemic Juvenile Arthritis Who Experience Laboratory Abnormalities During Treatment With RoActemra/Actemra (Tocilizumab)
PART1 Participants in Part 1 (Run-in-Phase) of study will receive tocilizumab (TCZ) (RoActemra/Actemra) 12 milligrams per kilogram (mg/kg) or 8 mg/kg intravenously (IV) every 2 weeks (Q2W) for up to 24 weeks.
- Trial name
- NCT01734382
- Testing
- Tocilizumab
- Where
- 19 sites in United States, Argentina and 8 more
- Volunteers
- 35 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Study on Safety and Efficacy of Tocilizumab (RoActemra/Actemra) Alone or in Combination With Non-Biologic Antirheumatics in Participants With Rheumatoid Arthritis
This multi-center, open-label single arm Phase IIIb study will evaluate the safety and efficacy of subcutaneous (SC) tocilizumab administered as monotherapy and/or in combination with methotrexate or other non-biologic disease…
- Trial name
- OSCAR (NCT01987479)
- Testing
- Non-Biologic DMARDs, Tocilizumab, Methotrexate
- Where
- 20 sites in Netherlands
- Volunteers
- 150 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Long-term Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients With Rheumatoid Arthritis
This open-label, international multi-center extension study WA18695 was designed to assess the long term safety of tocilizumab in patients who had moderate to severe active rheumatoid arthritis (RA).
- Trial name
- NCT00721123
- Testing
- Tocilizumab
- Where
- 69 sites in Argentina, Australia and 15 more
- Volunteers
- 538 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Non-Interventional Study of Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab) in Monotherapy
This observational study will evaluate the use and efficacy of RoActemra/Actemra (tocilizumab) in monotherapy in routine clinical practice in participants with rheumatoid arthritis.
- Trial name
- NCT01705730
- Testing
- tocilizumab
- Where
- 17 sites in Belgium
- Volunteers
- 71 people
- Sponsor
- Hoffmann-La Roche
COVID-19 Pneumonia
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia
This study will assess the pharmacodynamics, pharmacokinetics, safety and efficacy of two different doses of tocilizumab (TCZ) in combination with standard-of-care (SOC) in hospitalized adult participants with moderate to severe…
- Trial name
- MARIPOSA (NCT04363736)
- Testing
- Tociliuzumab
- Where
- 24 sites in United States
- Volunteers
- 97 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate Versus RoActemra/Actemra Monotherapy in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate
This randomized, double-blind, parallel-group study will evaluate the efficacy and safety of RoActemra/Actemra (tocilizumab) in combination with methotrexate versus RoActemra/Actemra monotherapy in patients with rheumatoid…
- Trial name
- NCT01399697
- Testing
- methotrexate, tocilizumab [RoActemra/Actemra]
- Where
- 54 sites in Spain
- Volunteers
- 261 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Study to Assess the Effect of Tocilizumab on Signs and Symptoms in Patients With Rheumatoid Arthritis
This single arm, open label study will assess the safety and efficacy, with regard to reduction of signs and symptoms,of treatment with tocilizumab in patients with moderate to severe active rheumatoid arthritis.
- Trial name
- NCT00848120
- Testing
- tocilizumab [RoActemra/Actemra]
- Where
- 4 sites in Philippines
- Volunteers
- 29 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Study of the Effect of Tocilizumab on Markers of Atherogenic Risk in Patients With Moderate to Severe Rheumatoid Arthritis
This 2 arm study will investigate the effects of tocilizumab on lipids, arterial stiffness, and markers of atherogenic risk in patients with moderate to severe active rheumatoid arthritis.
- Trial name
- NCT00535782
- Testing
- Tocilizumab, Methotrexate
- Where
- 40 sites in United States, Canada and 2 more
- Volunteers
- 132 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Study of RoActemra/Actemra (Tocilizumab) in Adult Patients With Rheumatoid Arthritis (SVOBODA Programme)
This open-label, single arm study evaluated the efficacy and safety of RoActemra/Actemra (tocilizumab) in patients with rheumatoid arthritis.
- Trial name
- NCT02010216
- Testing
- tocilizumab [RoActemra/Actemra]
- Where
- 6 sites in Kazakhstan
- Volunteers
- 23 people
- Sponsor
- Hoffmann-La Roche
Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma
Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma
This study will be separated into 3 distinct phases designated as the Phase 1 study, Phase 2 pivotal study (Cohort 1 and Cohort 2), and Phase 2 safety management study (Cohort 3 and Cohort 4, Cohort 5 and Cohort 6).
- Conditions
- Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma (TFL), Primary Mediastinal B-cell Lymphoma (PMBCL)
- Trial name
- ZUMA-1 (NCT02348216)
- Testing
- Axicabtagene Ciloleucel, Fludarabine, Cyclophosphamide
- Where
- 36 sites in United States, Canada and 4 more
- Volunteers
- 307 people
- Sponsor
- Kite, A Gilead Company
Rheumatoid Arthritis
A Study to Evaluate Tocilizumab Treatment in a Real-Life Setting
This observational, multi-center study will evaluate the treatment regimen, treatment responses and safety of tocilizumab therapy in a routine clinical practice in participants with moderate to severe rheumatoid arthritis (RA).
- Trial name
- NCT01664104
- Testing
- Tocilizumab
- Where
- 24 sites in Italy
- Volunteers
- 151 people
- Sponsor
- Hoffmann-La Roche